Annals of Surgical Oncology

, Volume 21, Issue 1, pp 240–247 | Cite as

Review of the Impact of Antineoplastic Therapies on the Risk for Cholelithiasis and Acute Cholecystitis

  • Thejus T. Jayakrishnan
  • Ryan T. Groeschl
  • Ben George
  • James P. Thomas
  • T. Clark Gamblin
  • Kiran K. Turaga
Gastrointestinal Oncology

Abstract

Background

Development of cholecystitis in patients with malignancies can potentially disrupt their treatment and alter prognosis. This review aims to identify antineoplastic interventions associated with increased risk of cholecystitis in cancer patients.

Methods

A comprehensive search strategy was developed to identify articles pertaining to risk factors and complications of cholecystitis in cancer patients. FDA-issued labels of novel antineoplastic drugs released after 2010 were hand-searched to identify more therapies associated with cholecystitis in nonpublished studies.

Results

Of an initial 2,932 articles, 124 were reviewed in the study. Postgastrectomy patients have a high (5–30 %) incidence of gallstone disease, and 1–7 % develop symptomatic disease. One randomized trial addressing the role of cholecystectomy concurrent with gastrectomy is currently underway. Among other risk groups, patients with neuroendocrine tumors treated with somatostatin analogs have a 15 % risk of cholelithiasis, and most are symptomatic. Hepatic artery based therapies carry a risk of cholecystitis (0.02–24 %), although the risk is reduced with selective catheterization. Myelosuppression related to chemotherapeutic agents (0.4 %), bone marrow transplantation, and treatment with novel multikinase inhibitors are associated with high risk of cholecystitis.

Conclusions

There are several risk factors for gallbladder-related surgical emergencies in patients with advanced malignancies. Incidental cholecystectomy at index operation should be considered in patients planned for gastrectomy, and candidates for regional therapies to the liver or somatostatin analogs. While prophylactic cholecystectomy is currently recommended for patients with cholelithiasis receiving myeloablative therapy, this strategy may have value in patients treated with multikinase inhibitors, immunotherapy, and oncolytic viral therapy based on evolving evidence.

References

  1. 1.
    Sanders G, Kingsnorth AN. Gallstones. BMJ. 2007;335:295–299.PubMedCrossRefGoogle Scholar
  2. 2.
    Thomsen RW, Thomsen HF, Norgaard M, Cetin K, McLaughlin JK, Tarone RE, et al. Risk of cholecystitis in patients with cancer: a population-based cohort study in Denmark. Cancer. 2008;113:3410–3419.PubMedCrossRefGoogle Scholar
  3. 3.
    Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda: National Cancer Institute, 2012.Google Scholar
  4. 4.
    Giger UF, Michel JM, Opitz I, Th Inderbitzin D, Kocher T, Krahenbuhl L. Risk factors for perioperative complications in patients undergoing laparoscopic cholecystectomy: analysis of 22,953 consecutive cases from the Swiss Association of Laparoscopic and Thoracoscopic Surgery database. J Am Coll Surg. 2006;203:723–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Kim J, Cho JN, Joo SH, Kim BS, Lee SM. Multivariable analysis of cholecystectomy after gastrectomy: laparoscopy is a feasible initial approach even in the presence of common bile duct stones or acute cholecystitis. World J Surg. 2012;36: 638–44.PubMedCrossRefGoogle Scholar
  6. 6.
    Kwon AH, Inui H, Imamura A, Kaibori M, Kamiyama Y. Laparoscopic cholecystectomy and choledocholithotomy in patients with a previous gastrectomy. J Am Coll Surg. 2001;193:614–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Akatsu T, Yoshida M, Kubota T, Shimazu M, Ueda M, Otani Y, et al. Gallstone disease after extended (D2) lymph node dissection for gastric cancer. World J Surg. 2005;29:182–6.PubMedCrossRefGoogle Scholar
  8. 8.
    McCrudden R, Williams DB, O’Connor T, Vickers CR. Gastrointestinal, hepatic, gallbladder, pancreatic, and perianal complications. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge, U.K.: Cambridge University Press, 2004:1417–1453.Google Scholar
  9. 9.
    Wu CC, Chen CY, Wu TC, Iiu TJ, P’Eng P K. Cholelithiasis and cholecystitis after gastrectomy for gastric carcinoma: a comparison of lymphadenectomy of varying extent. Hepatogastroenterology. 1995;42:867–872.PubMedGoogle Scholar
  10. 10.
    Kobayashi T, Hisanaga M, Kanehiro H, Yamada Y, Ko S, Nakajima Y. Analysis of risk factors for the development of gallstones after gastrectomy. Br J Surg. 2005;92:1399–1403.PubMedCrossRefGoogle Scholar
  11. 11.
    Gillen S, Michalski CW, Schuster T, Feith M, Friess H, Kleeff J. Simultaneous/Incidental cholecystectomy during gastric/esophageal resection: systematic analysis of risks and benefits. World J Surg. 2010;34:1008–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Bernini M, Bencini L, Sacchetti R, Marchet A, Cristadoro L, Pacelli F, et al. The Cholegas Study: safety of prophylactic cholecystectomy during gastrectomy for cancer: preliminary results of a multicentric randomized clinical trial. Gastric Cancer. 2013;16:370–376.PubMedCrossRefGoogle Scholar
  13. 13.
    Kodama I, Yoshida C, Kofuji K, Ohta J, Aoyagi K, Takeda J. Gallstones and gallbladder disorder after gastrectomy for gastric cancer. Int Surg. 1996;81:36–39.PubMedGoogle Scholar
  14. 14.
    Toumpanakis C, Caplin ME. Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol. 2013;40:56–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Takacs T, Hajnal F, Nemeth J, Lonovics J, Pap A. Stimulated gastrointestinal hormone release and gallbladder contraction during continuous jejunal feeding in patients with pancreatic pseudocyst is inhibited by octreotide. Int J Pancreatol. 2000;28:215–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Niv Y, Charash B, Sperber AD, Oren M. Effect of octreotide on gastrostomy, duodenostomy, and cholecystostomy effluents: a physiologic study of fluid and electrolyte balance. Am J Gastroenterol. 1997;92:2107–11.PubMedGoogle Scholar
  17. 17.
    Norlen O, Hessman O, Stalberg P, Akerstrom G, Hellman P. Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg. 2010;34:1361–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–4663.PubMedCrossRefGoogle Scholar
  19. 19.
    Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer. 1997;79:830–834.PubMedCrossRefGoogle Scholar
  20. 20.
    Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66:859–68.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab. 2003;88:5258–65.PubMedCrossRefGoogle Scholar
  22. 22.
    Gurusamy KS, Koti R, Fusai G, Davidson BR. Somatostatin analogues for pancreatic surgery. Cochrane Database Syst Rev. 2012;6:CD008370.PubMedGoogle Scholar
  23. 23.
    Rahbour G, Siddiqui MR, Ullah MR, Gabe SM, Warusavitarne J, Vaizey CJ. A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Ann Surg. 2012;256:946–54.PubMedCrossRefGoogle Scholar
  24. 24.
    Coughlin S, Roth L, Lurati G, Faulhaber M. Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World J Surg. 2012;36:1016–29.PubMedCrossRefGoogle Scholar
  25. 25.
    Michielsen PP, Fierens H, Van Maercke YM. Drug-induced gallbladder disease. Incidence, aetiology and management. Drug Saf. 1992;7:32–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Gorschluter M, Mey U, Strehl J, Schepke M, Lamberti C, Sauerbruch T, et al. Cholecystitis in neutropenic patients: retrospective study and systematic review. Leuk Res. 2006;30:521–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Indar AA, Beckingham IJ. Acute cholecystitis. BMJ. 2002;325:639–43.Google Scholar
  28. 28.
    Jones AD, Maziarz R, Gilster J, Domreis J, Deveney CW, Sheppard BC. Surgical complications of bone marrow transplantation. Am J Surg. 2003;185:481–484.PubMedCrossRefGoogle Scholar
  29. 29.
    McDonald GB. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology. 2010;51:1450–1460.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Gomez-Abuin G, Karam AA, Mezzadri NA, Bas CA. Acalculous cholecystitis in a patient with metastatic renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer. 2009;7:62–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Nakano K, Suzuki K, Morita T. Life-threatening acute acalculous cholecystitis in a patient with renal cell carcinoma treated by sunitinib: a case report. J Med Case Rep. 2012;6:69.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Aihara Y, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Morioka C, et al. A case of severe acalculous cholecystitis associated with sorafenib treatment for advanced hepatocellular carcinoma. World J Gastrointest Oncol. 2012;4:115–8.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Cetin B, Coskun U, Yildiz R, Buyukberber S, Baykara M, Benekli M. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus. J Oncol Pharm Pract. 2011;17:274–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Premkumar A, Walworth CM, Vogel S, Daryanani KD, Venzon DJ, Kovacs JA, et al. Prospective sonographic evaluation of interleukin-2-induced changes in the gallbladder. Radiology. 1998;206:393–6.PubMedGoogle Scholar
  35. 35.
    Marti JK, Banks KP, Song WS. Novel use of hepatobiliary scintigraphy for the diagnosis of interleukin-2 cholangiopathy. Hell J Nucl Med. 2010;13:163–5.PubMedGoogle Scholar
  36. 36.
    Choi JW, Lee JS, Kim SW, Yun CO. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev. 2012;64:720–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Sugio K, Sakurai F, Katayama K, Tashiro K, Matsui H, Kawabata K, et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res. 2011;17:2807–18.PubMedCrossRefGoogle Scholar
  38. 38.
    Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011;17:581–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V, et al. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res. 2010;16:3035–3043.PubMedCrossRefGoogle Scholar
  40. 40.
    Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012;72:1621–1631.PubMedCrossRefGoogle Scholar
  41. 41.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery. 1993;114:928–935.PubMedGoogle Scholar
  43. 43.
    Cohen AD, Kemeny NE. An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist. 2003;8:553–66.PubMedCrossRefGoogle Scholar
  44. 44.
    McWilliams JP, Kee ST, Loh CT, Lee EW, Liu DM. Prophylactic embolization of the cystic artery before radioembolization: feasibility, safety, and outcomes. Cardiovasc Intervent Radiol. 2011;34:786–792.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Wagnetz U, Jaskolka J, Yang P, Jhaveri KS. Acute ischemic cholecystitis after transarterial chemoembolization of hepatocellular carcinoma: incidence and clinical outcome. J Comput Assist Tomogr. 2010;34:348–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Sun Z, Li G, Ai X, Luo B, Wen Y, Zhao Z, et al. Hepatic and biliary damage after transarterial chemoembolization for malignant hepatic tumors: incidence, diagnosis, treatment, outcome and mechanism. Crit Rev Oncol Hematol. 2011;79:164–74.PubMedCrossRefGoogle Scholar
  47. 47.
    Miller FH, Keppke AL, Reddy D, Huang J, Jin J, Mulcahy MF, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. Am J Roentgenol. 2007;188:776–83.CrossRefGoogle Scholar
  48. 48.
    Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, et al. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol. 2012;23:96–105.PubMedCrossRefGoogle Scholar
  49. 49.
    Jakobs TF, Hoffmann RT, Dehm K, Trumm C, Stemmler HJ, Tatsch K, et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol. 2008;19:1187–95.PubMedCrossRefGoogle Scholar
  50. 50.
    Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19:691–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Chopra S, Dodd GD, 3rd, Chanin MP, Chintapalli KN. Radiofrequency ablation of hepatic tumors adjacent to the gallbladder: feasibility and safety. Am J Roentgenol. 2003;180:697–701.CrossRefGoogle Scholar
  52. 52.
    Sasaki A, Nakajima J, Nitta H, Obuchi T, Baba S, Wakabayashi G. Laparoscopic cholecystectomy in patients with a history of gastrectomy. Surg Today. 2008;38:790–794.PubMedCrossRefGoogle Scholar
  53. 53.
    Oh SJ, Choi WB, Song J, Hyung WJ, Choi SH, Noh SH. Complications requiring reoperation after gastrectomy for gastric cancer: 17 years experience in a single institute. J Gastrointest Surg. 2009;13:239–45.PubMedCrossRefGoogle Scholar
  54. 54.
    Fukagawa T, Katai H, Saka M, Morita S, Sano T, Sasako M. Gallstone formation after gastric cancer surgery. J Gastrointest Surg. 2009;13:886–889.PubMedCrossRefGoogle Scholar
  55. 55.
    Isayama H, Kawabe T, Nakai Y, Tsujino T, Sasahira N, Yamamoto N, et al. Cholecystitis after metallic stent placement in patients with malignant distal biliary obstruction. Clin Gastroenterol Hepatol. 2006;4:1148–1153.PubMedCrossRefGoogle Scholar
  56. 56.
    Malagari K, Pomoni M, Spyridopoulos TN, Moschouris H, Kelekis A, Dourakis S, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol. 2011;34:774–785.PubMedCrossRefGoogle Scholar
  57. 57.
    Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31:269–280.PubMedCrossRefGoogle Scholar
  58. 58.
    Pietrosi G, Miraglia R, Luca A, Vizzini GB, Fili’ D, Riccardo V, et al. Arterial chemoembolization/embolization and early complications after hepatocellular carcinoma treatment: a safe standardized protocol in selected patients with Child class A and B cirrhosis. J Vasc Interv Radiol. 2009;20:896–902.PubMedCrossRefGoogle Scholar
  59. 59.
    Nishiofuku H, Tanaka T, Matsuoka M, Otsuji T, Anai H, Sueyoshi S, et al. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study. J Vasc Interv Radiol. 2013;24:56–65.PubMedCrossRefGoogle Scholar
  60. 60.
    Katayose Y, Rikiyama T, Motoi F, Yamamoto K, Yoshida H, Morikawa T, et al. Phase I trial of neoadjuvant chemoradiation with gemcitabine and surgical resection for cholangiocarcinoma patients (NACRAC study). Hepatogastroenterology. 2011;58:1866–1872.PubMedGoogle Scholar
  61. 61.
    Akin ML, Uluutku H, Erenoglu C, Karadag A, Gulluoglu BM, Sakar B, et al. Tamoxifen and gallstone formation in postmenopausal breast cancer patients: retrospective cohort study. World J Surg. 2003;27:395–399.PubMedCrossRefGoogle Scholar
  62. 62.
    Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2009:CD004143.Google Scholar
  63. 63.
    Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011;29:3869–3876.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Thejus T. Jayakrishnan
    • 1
  • Ryan T. Groeschl
    • 1
  • Ben George
    • 2
  • James P. Thomas
    • 2
  • T. Clark Gamblin
    • 1
  • Kiran K. Turaga
    • 1
  1. 1.Division of Surgical Oncology, Department of SurgeryMedical College of WisconsinMilwaukeeUSA
  2. 2.Division of Medical OncologyMedical College of WisconsinMilwaukeeUSA

Personalised recommendations